-
-
-
-
-
-
-
Ardelyx (ARDX) says FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments for Tenapanor at this time
-
-
-
-
-
-
-
Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
-
-
-
-
-
-
-
Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors
-
-
-
-
-
-
-
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
-
-
-
-
-
-
Ardelyx (ARDX) Announces FDA Acceptance for Filing of its NDA of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
-
-
-
-
-
-
-
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
-
-
-
-
-
-
-
Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

